Current Assessment of Risk–Benefit by Regulators: Is It Time to Introduce Decision Analyses?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference30 articles.
1. A model for the future conduct of pharmacovigilance
2. Risk Within Reason
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A proposal for using benefit-risk methods to improve the prominence of adverse event results when reporting trials;Trials;2024-06-22
2. Benefit-Risk Assessment of Medical Products Using Bayesian Multi-Criteria Augmented Decision Analysis (MCADA) for Clinical Development;2023-09-02
3. A comparison of various aggregation functions in multi-criteria decision analysis for drug benefit–risk assessment;Statistical Methods in Medical Research;2022-01-19
4. Patient‐Focused Drug Development Methods for Benefit–Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs;Clinical Pharmacology & Therapeutics;2018-10-25
5. A novel measure of drug benefit–risk assessment based on Scale Loss Score;Statistical Methods in Medical Research;2018-07-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3